— Why it moved
Why ENTX Stock Doubled, Then Fizzled Today — June 22, 2026
Genuine FDA news doubled the stock by midday. The spike topped the same minute Stock Pulse flagged it, then gave nearly all of it back into the close.
What moved ENTX stock
Entera Bio is a clinical-stage biotech developing EB613, an oral parathyroid-hormone tablet for postmenopausal osteoporosis. Real news for once: the FDA gave positive feedback on its registrational Phase 3 protocol — one placebo-controlled trial in about 750 women, hip bone density at 12 months as the endpoint, and a clearer path to an NDA filing.
The mechanics
Not a microfloat toy this time: a 40M-share float and a ~$60M cap, but volume ran to about 51M shares against a 30-day average under 100K. When a sleepy biotech gets a de-risking headline, the first hours belong to momentum chasers.
ENTX by the numbers
The alert window
Stock Pulse alerted at 12:32 PM at $2.64, and the peak $2.68 printed in that same minute. The alert minute was the top. No window — it never traded there again.
How ENTX's move ended
It slid all afternoon and closed at $1.49: 44% below the alert, though still up 23% on the day. The chasers left as fast as they arrived, and what remains is a clinical-stage company with no approved product and a Phase 3 that still has to be funded, run, and passed.
The tell: genuine news doesn't exempt a stock from the fade — a doubling that's already hours old by midday has spent its buyers, and an alert firing into a mature spike catches the exit, not the entry.